The Turn Stalls: Organic Rounds to Zero, Share Slips to an Eight-Year Low, and the First FY27 Guide Lands Under the Street
Key Takeaways
- The reacceleration we graded "confirmed" one quarter ago did not hold. Q4 organic sales rounded to zero, volume, pricing and mix were each neutral, and only 6 of 10 categories and 5 of 7 regions held or grew organic sales, versus 10 of 10 and 7 of 7 in Q3. Fiscal 2026 closed at +1% organic, a step down from +2% in fiscal 2025 and the weakest full-year reading since fiscal 2019.
- Profit fell in every reportable segment. Beauty net earnings dropped 19%, Grooming 15%, Baby/Feminine/Family Care 13%, Health Care 10% and Fabric & Home Care 10%, even though four of the five grew net sales. Core operating margin contracted 130 bps on a 130 bps step-up in core SG&A, and core EPS of $1.43 fell 3% (down 5% currency-neutral), the first negative core-EPS quarter in eight.
- The two-cent EPS beat is the lowest-quality kind. Core gross margin held exactly flat only because 40 bps of net tariff-recovery benefit offset 40 bps of higher commodity cost; without the recovery the same bridge nets to minus 40 bps. A 100 bps lower core tax rate added roughly two cents more.
- The first fiscal 2027 guide, deferred from April, arrived below the Street on both lines: core EPS of $6.89 to $7.11 (midpoint $7.00) against consensus near $7.04, and organic sales of 1% to 3% against roughly 2.7%. The $1B after-tax input-cost headwind did not shrink even though the assumed Brent price fell from about $100 to $90, and management pre-announced that Q1 core EPS will be down 5% or more.
- Rating: Downgrading to Underperform from Hold. Our Q3 note named two downgrade triggers, Q4 organic falling materially below ~2% and productivity offsets visibly falling short of the oil headwind; both fired. At roughly 21x a fiscal 2027 core number the company itself guides to 0% to 3% growth, the multiple has no growth to defend and the ~3.0% yield does not close the gap.
Results vs. Consensus
P&G cleared the earnings bar and missed everything else. The two-cent core-EPS beat is the only line in the print that came in ahead, and it arrived alongside a revenue miss, flat organic sales, a 130 bps contraction in core operating margin, and a 3% year-over-year decline in core EPS. Set against a quarter in which management's own framing at the April call was that Q4 would be "somewhat lower" than Q3, the result is not a surprise so much as a confirmation that the second-half inflection was narrower than it looked.
Q4 FY2026 scorecard
| Metric | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Net sales | $21.203B | $21.38B | Miss | -0.8% |
| Organic sales growth | 0% | ~+1% | Miss | ~1 pt short |
| Core EPS | $1.43 | $1.41 | Beat | +$0.02 (+1.4%) |
| GAAP diluted EPS | $1.26 | n/a | Down YoY | -15% |
| Core gross margin | 49.1% | n/a | Flat YoY | 0 bps |
| Core operating margin | 19.5% | n/a | Down YoY | -130 bps |
| Adjusted FCF productivity | 133% | n/a | Strong | vs. 85%-90% FY guide |
Year-over-year comparison
| Metric | Q4 FY26 | Q4 FY25 | Change |
|---|---|---|---|
| Net sales ($M) | 21,203 | 20,889 | +2% |
| Gross profit ($M) | 10,283 | 10,258 | 0% |
| SG&A ($M) | 6,334 | 5,903 | +7% |
| Operating income ($M) | 3,949 | 4,355 | (9)% |
| Net earnings attributable to P&G ($M) | 3,044 | 3,615 | (16)% |
| GAAP diluted EPS | $1.26 | $1.48 | (15)% |
| Core EPS | $1.43 | $1.48 | (3)% |
| Currency-neutral core EPS | $1.41 | $1.48 | (5)% |
| Gross margin | 48.5% | 49.1% | (60) bps |
| Core gross margin | 49.1% | 49.1% | flat |
| Core operating margin | 19.5% | 20.8% | (130) bps |
| Effective tax rate (GAAP) | 21.7% | 19.8% | +190 bps |
| Diluted weighted average shares (M) | 2,412.7 | 2,443.8 | (1.3)% |
Sequential comparison (vs. Q3 FY2026)
| Metric | Q3 FY26 | Q4 FY26 | Trend |
|---|---|---|---|
| Organic sales growth | +3% | 0% | decelerated 3 pts |
| Core EPS | $1.59 | $1.43 | -10% sequentially |
| Core EPS growth (YoY) | +3% | (3)% | turned negative |
| Core gross margin | 50.0% | 49.1% | (90) bps |
| Core operating margin | 22.2% | 19.5% | (270) bps |
| North America organic | +4% | (1)% | swung negative |
| Categories holding or growing organic | 10 of 10 | 6 of 10 | narrowed |
| Regions holding or growing organic | 7 of 7 | 5 of 7 | narrowed |
| Greater China organic | +3% | +4% | accelerated |
Fiscal 2026 in full
| Metric | FY2026 | FY2025 | Change |
|---|---|---|---|
| Net sales ($M) | 87,032 | 84,284 | +3% |
| Organic sales growth | +1% | +2% | decelerated |
| Operating income ($M) | 19,748 | 20,451 | (3)% |
| Net earnings attributable to P&G ($M) | 16,046 | 15,974 | 0% |
| GAAP diluted EPS | $6.62 | $6.51 | +2% |
| Core EPS | $6.89 | $6.83 | +1% |
| Currency-neutral core EPS | $6.80 | n/a | 0% vs. prior core |
| Core gross margin | 50.7% | 51.1% | (40) bps |
| Core operating margin | 23.6% | 24.3% | (70) bps |
| Operating cash flow ($M) | 19,556 | 17,817 | +10% |
| Adjusted free cash flow ($M) | 15,835 | n/a | 100% productivity |
| Capital returned ($B) | 15.3 | 16.4 | (7)% |
| Top-50 combinations holding or growing share | 26 | 29 | (3) |
The four reported quarters sum exactly to the full-year figures: net sales of $22,386M, $22,208M, $21,235M and $21,203M total $87,032M, and core EPS of $1.99, $1.88, $1.59 and $1.43 totals $6.89. Fiscal 2026 therefore landed inside every going-in guidance range, which is the fact management leads with, and at or near the bottom of most of them, which is the fact that matters.
Quality of the beat. This is the weakest-quality print P&G has delivered in the two years we have examined. Three observations:
- The gross-margin hold was bought, not earned. Core gross margin was flat because 160 bps of productivity, 40 bps of net tariff-recovery benefit, 20 bps of miscellaneous items and 10 bps of pricing exactly offset 120 bps of unfavorable product mix, 70 bps of product and package reinvestment, and 40 bps of higher commodity cost. Strip the tariff recovery, a recovery of amounts previously paid rather than an operating improvement, and the same bridge nets to minus 40 bps.
- Tax helped on the core line. The headline GAAP tax rate rose 190 bps to 21.7%, but that is an artifact of restructuring charges carrying little tax benefit. On a core basis the rate was 18.8% against 19.8% a year earlier, worth roughly two cents. The reported beat was two cents.
- Buybacks absorbed a third of the earnings decline. Core net earnings attributable to P&G fell 4.8%; core EPS fell 3%. The 1.3% reduction in diluted shares covered the difference.
Assessment: Revenue
Net sales of $21.203B grew 2%, and every point of that came from foreign exchange and rounding. Volume, pricing and mix were each neutral. Organic sales rounded to zero, which is the floor of the 0% to 4% range P&G guided the year to matching the flat reading of the December quarter two periods earlier.
Management offered three progressively adjusted versions of the number and it is worth being precise about which is which. The reported figure is 0%. Excluding the deliberate brand, product-form and go-to-market discontinuations, it is roughly 1%. Adding back the point of Easter-related trade inventory that pulled forward into Q3, it is roughly 2%, which management describes as "consistent structural growth of 2% across the second half of the year."
"Adjusting for brand, product and go-to-market restructuring impacts, organic sales for the ongoing business were around 1% for the quarter. 2% when adjusting for 1 point of pull-forward into Q3, consistent structural growth of 2% across the second half of the year"
— Andre Schulten, CFO
The 2% construct is defensible arithmetic, and we accepted the pull-forward adjustment in the other direction last quarter when it flattered Q3. What it is not is an acceleration. A company whose long-term algorithm is 3% to 5% has now delivered a second-half structural run rate of 2%, a full year of 1%, and a fiscal-2027 guide whose midpoint is 2%. The direction of travel over three consecutive fiscal years is 2%, then 1%, then a guided 2% at the middle. That is a business holding position, not a business inflecting.
Assessment: Margins
The interesting thing about the margin line this quarter is where the pressure moved. Core gross margin was flat, an improvement on the 100 bps of compression in Q3. All of the operating-margin damage came from below the gross-profit line: core SG&A rose 130 bps as a percentage of sales, with 410 bps of reinvestment (primarily marketing) and 20 bps of other items partially offset by 300 bps of productivity. Total gross productivity inside core operating margin ran at 460 bps, a genuinely strong number, and the company still lost 130 bps of margin.
That is a deliberate choice rather than a loss of control, and management said so repeatedly. But the arithmetic of the choice is now unforgiving. P&G spent 410 bps of incremental marketing in the quarter and organic sales came in at zero, with the top-50 share metric at 23 for the quarter and 26 for the year. The reinvestment case rests on the proposition that this spend buys share, and in fiscal 2026 it did not.
Assessment: EPS
Core EPS of $1.43 fell 3% and 5% currency-neutral, the first negative core-EPS quarter in the eight-quarter series P&G publishes and the weakest quarter of a year in which the pattern ran +3%, 0%, +3%, then -3%. GAAP diluted EPS of $1.26 fell 15%, carrying $0.16 of incremental restructuring against a prior-year quarter with no core adjustments at all.
The full-year picture is where the deceleration is clearest. Core EPS of $6.89 grew 1% and was flat currency-neutral. In the nine-year series the company discloses, that is the weakest reading: the prior eight years ran +7%, +13%, +11%, +3%, +2%, +12%, +4%, and now +1%. Currency-neutral, fiscal 2026 is the only year in the series with no growth at all.
Segment Performance
The segment table carries the quarter's single most arresting fact: net earnings fell double digits in all five reportable segments, and four of the five grew net sales while doing it. Corporate absorbed a $194M pre-tax loss. This is not a mix story in which one weak business drags the average; it is a company-wide compression in which the marketing step-up and commodity costs landed everywhere at once.
Q4 FY2026 reportable segments
| Segment | Net sales ($M) | Net sales growth | Organic sales | Organic volume | Earnings before taxes ($M) | Net earnings ($M) | Net earnings growth | Pre-tax margin |
|---|---|---|---|---|---|---|---|---|
| Beauty | 3,975 | +6% | +4% | +3% | 588 | 450 | (19)% | 14.8% |
| Grooming | 1,699 | +1% | 0% | (1)% | 414 | 317 | (15)% | 24.4% |
| Health Care | 2,757 | +1% | (1)% | (3)% | 449 | 336 | (10)% | 16.3% |
| Fabric & Home Care | 7,432 | +1% | 0% | +1% | 1,598 | 1,233 | (10)% | 21.5% |
| Baby, Feminine & Family Care | 5,049 | (1)% | (2)% | (1)% | 1,078 | 825 | (13)% | 21.3% |
| Corporate | 292 | n/a | n/a | n/a | (194) | (80) | n/a | n/a |
| Total P&G | 21,203 | +2% | 0% | 0% | 3,933 | 3,081 | (15)% | 18.5% |
Pre-tax margin is each segment's own earnings before income taxes divided by its own net sales. The Total row is the income-statement figure; the five segments plus Corporate sum to $21,204M, a $1M rounding difference.
Q4 FY2026 net sales drivers
| Segment | Volume | Foreign exchange | Price | Mix | Other | Net sales |
|---|---|---|---|---|---|---|
| Beauty | 3% | 2% | 1% | 0% | 0% | 6% |
| Grooming | (1)% | 1% | 1% | (1)% | 1% | 1% |
| Health Care | (3)% | 2% | 2% | 1% | (1)% | 1% |
| Fabric & Home Care | 1% | 0% | 0% | 0% | 0% | 1% |
| Baby, Feminine & Family Care | (1)% | 1% | (1)% | 0% | 0% | (1)% |
| Total P&G | 0% | 1% | 0% | 0% | 1% | 2% |
Q4 FY2026 category and regional detail
| Growth band | Categories (6 of 10 held or grew) |
|---|---|
| Mid single digits | Personal Health Care, Hair Care, Skin & Personal Care |
| In line to up low singles | Baby Care, Fabric Care, Grooming |
| Down | Home Care, Feminine Care, Family Care, Oral Care |
| Region | Q4 organic sales | Read |
|---|---|---|
| Focus markets (aggregate) | (1)% | The developed core turned negative after +4% North America in Q3 |
| North America | (1)% | Consumption +2%, shipments -1%; a 3-point sell-out to sell-in gap |
| European focus markets | (1)% | Same inventory and value dynamics as the US, plus retailer negotiation windows |
| Greater China | +4% | Positive again and +4% for the fiscal year; share growth for the first time in 15 quarters |
| Enterprise markets (aggregate) | +4% | Broad-based and the most consistent part of the portfolio |
| Europe enterprise markets | +5% | Strongest region in the quarter |
| Latin America | +4% | +6% for the fiscal year; Mexico gained over a point of value share |
| Asia Pacific, Middle East, Africa | +3% | Closer to +6% excluding deliberate market exits |
Beauty
Beauty was the only segment with meaningful organic growth, up 4% on 3 points of volume and 1 point of price, and it was still the segment whose profit fell the most. Net earnings dropped 19% as sales growth, productivity and tariff recovery were more than offset by marketing investment, higher commodity costs and product mix. Underneath, Hair Care and Personal Care each grew mid single digits, while Skin Care organic sales were unchanged as favorable mix from the super-premium SK-II line offset a volume decline in Greater China. On share, Personal Care held, Hair Care lost 0.2 points and Skin Care lost 0.5 points.
Assessment: Beauty remains the best demand story in the portfolio and is now also the clearest illustration of the company's central problem. Growing organic sales 4% while losing share in two of three sub-categories and shedding 19% of profit is not the "superiority earns pricing plus volume" model working. It is the model being funded at a price the P&L can no longer absorb.
Fabric & Home Care
The largest segment, at 35% of company net sales, delivered flat organic growth on 1 point of volume. Fabric Care grew low single digits on volume led by Europe and favorable mix, partially offset by merchandising investment in North America; Home Care declined low single digits on a North American volume decline. Both sub-categories held global value share in line with the prior year. Net earnings fell 10% as productivity and tariff recovery were more than offset by product investment, commodity costs and marketing.
The strategic centerpiece here is the Tide relaunch, which management continues to hold up as the proof of concept for the "stronger core" idea: the biggest formula upgrade to original Tide liquid in more than two decades, delivered at an unchanged price, taking that business from decline to high-single-digit growth.
"Tide did their biggest upgrade in over two decades on their original Tide liquid detergent, which represents more than one-fourth of all Tide detergent users. Significantly improving the product for the same price. Since launch, Tide Original Liquid has gone from declining to high-single-digit growth."
— Shailesh Jejurikar, President and CEO
Assessment: The Tide result is real and, in isolation, impressive. The problem is scale of effect: the single most successful intervention in the portfolio, applied to more than a quarter of the users of P&G's largest brand, produced a segment that grew organic sales 0%. Whatever Tide added, merchandising investment and Home Care took back.
Baby, Feminine & Family Care
The weakest segment, with organic sales down 2% on a 1-point volume decline and 1 point of negative pricing, the only segment where pricing was a drag. Baby Care organic sales grew low single digits led by Greater China volume, Feminine Care declined low single digits on a European volume decline, and Family Care fell mid single digits on volume, merchandising investment and unfavorable mix. Share moved down in two of three: Baby Care gained 0.2 points, Feminine Care lost 0.2 and Family Care lost 0.4.
Family Care is the structural question inside this segment. It was the only P&G category to decline for the full fiscal year, and it is the category most exposed to private-label price gaps.
"this is a category where price points matter a lot versus private label. And with the commodity-based pricing, we have gotten too far away from a price point perspective in some channels. So that correction is happening. And one encouraging sign to leave you with is we have grown users for the first time in Family Care in the most recent period."
— Andre Schulten, CFO
Assessment: The user-growth data point is the first genuinely forward-looking positive in this category in several quarters, and it precedes the innovation management says is coming. But "we have gotten too far away from a price point" is an admission that the correction runs through price, not through premium innovation, which means the recovery in this segment arrives margin-dilutive.
Health Care
Health Care declined 1% organic on a 3-point volume decline, the steepest volume erosion in the portfolio, offset by 2 points of price and 1 of mix. The split inside was wide: Personal Health Care grew mid single digits on price and North American volume and gained 0.6 points of global value share, the best share performance of any category disclosed. Oral Care fell mid single digits on volume declines led by North America and Greater China and lost 0.3 points of share. Net earnings fell 10%.
Assessment: Personal Health Care is quietly the strongest share performer in the company. Oral Care is the offsetting problem, and management's own framing on the China piece was that the team is "actively deciding what we want to do in that space," which is unusually open language for a business P&G has competed in for decades. Watch whether the Oral Care answer eventually becomes a portfolio answer.
Grooming
Grooming organic sales were unchanged as innovation-based pricing offset a volume decline concentrated in the Middle East and Africa and unfavorable product mix. Global Grooming value share fell 0.2 points and net earnings fell 15%. The bright spot management volunteered was the vertical portfolio, with an at-home laser hair-removal device priced around $300 cited as one of the best-performing items in the segment.
Assessment: Grooming is the segment where the "vertical portfolio" argument is most concrete, and it is a genuine competitive asset in a soft-demand environment. It is also an 8%-of-company-sales business that grew organic sales 0%. The strategic point is sound and the financial contribution is not yet visible.
Fiscal 2026 segments
| Segment | Net sales ($M) | Net sales growth | Earnings before taxes ($M) | Net earnings ($M) | Net earnings growth |
|---|---|---|---|---|---|
| Beauty | 16,023 | +7% | 3,473 | 2,672 | (2)% |
| Grooming | 6,918 | +4% | 1,966 | 1,529 | (3)% |
| Health Care | 12,456 | +4% | 3,163 | 2,404 | (1)% |
| Fabric & Home Care | 30,314 | +2% | 7,290 | 5,632 | (4)% |
| Baby, Feminine & Family Care | 20,401 | +1% | 5,145 | 3,930 | (2)% |
| Corporate | 919 | n/a | (660) | (23) | n/a |
| Total P&G | 87,032 | +3% | 20,377 | 16,144 | 0% |
Assessment: Every reportable segment grew net sales for the fiscal year and every reportable segment shrank net earnings. Because every segment's profit declined while the company total was flat, the offset came from the Corporate line, which carries the $261M after-tax gain on the Glad joint-venture dissolution. That divergence between top-line and segment profit is the fiscal-2026 story in one table.
Key Topics & Management Commentary
Overall Management Tone: Management was measured and process-oriented, leaning throughout on adjusted versions of the organic number and on regional proof points rather than on the consolidated result. The posture shifted from Q3's "the plan is working, but a macro cloud just rolled in" to a steadier "the plan is working underneath, give it another semester," delivered without defensiveness but also without the confidence spike that accompanied the Q3 inflection. The least convincing stretch came on margins, where a direct analyst premise about gross-margin compression and SG&A leverage was answered with a description of the investment philosophy rather than with the requested direction of travel.
1. Organic sales rounded to zero, and the three numbers management wants you to use instead
The reported organic figure is 0%: volume, pricing and mix each neutral. Management immediately supplied two adjusted versions, roughly 1% excluding deliberate discontinuations and roughly 2% adding back the Easter-related pull-forward into Q3, and framed the second half as delivering "consistent structural growth of 2%." Both adjustments are legitimate and we applied the pull-forward one symmetrically last quarter, when it flattered the Q3 headline.
What the adjustments cannot do is change the fiscal-year outcome. Fiscal 2026 organic growth of 1% is a step down from fiscal 2025's 2%, and the four-quarter path ran +2%, 0%, +3%, 0%. There is no trend line in that sequence, only alternation.
"As we mentioned before, the growth trajectory has not been and will not be a straight line quarter to quarter."
— Andre Schulten, CFO
Assessment: The non-linearity framing is fair, and we would accept it as an explanation for one quarter. Applied across a full fiscal year in which the annual result decelerated, it stops being an explanation of variance and starts being a description of the level. The level is 1% to 2%, against a 3% to 5% long-term algorithm.
2. The North American shipment-consumption gap
The most-discussed operational item on the call was a 3-point gap in North America between what consumers bought and what P&G shipped. Consumption ran +2% while sell-in ran -1%, producing a -1% organic result in the company's largest and most profitable market, one quarter after that same market printed +4%.
"Organic sales in North America were down 1% versus prior year, while consumption and market share of P&G brands improved, through the quarter, there was a notable disconnect between sell-out and sell-in, with sell-out or consumption at +2% and sell-in at -1%. The shift of Amazon Prime Day to late June versus early July drove an increase in merchandising spending recognized in the quarter, retailer inventory reductions, including the pull-forward into last quarter, also contributed to the 3-point gap between sell-out and sell-in."
— Andre Schulten, CFO
Management attributed the gap to three things: the Prime Day calendar shift pulling merchandising spend into the quarter, retailer destocking, and the reversal of the Q3 pull-forward. It also declined to describe the dynamic as behind it, saying instead that the fix is faster underlying growth.
"We have to deliver stronger growth, and that is what they are working on."
— Andre Schulten, CFO
Assessment: The consumption number is the encouraging half and we do not dismiss it: +2% consumption with improving share is a better leading indicator than shipments. But P&G reports shipments, and management's own answer is that the gap persists until growth is high enough to hide it. That is an admission that the reported line will stay noisy, which for a stock whose multiple is paid for predictability is itself a cost.
3. Market share: 26 of 50, and the fiscal-year exit
P&G held or grew value share in 23 of its top 50 category-country combinations in the quarter and 26 for the fiscal year. The company's own ten-year chart puts fiscal 2026 level with fiscal 2018 and below every year in between, against a peak of 38 in fiscal 2022 and 29 last year. Five of ten product categories held or grew global share for the year.
| Fiscal year | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 |
|---|---|---|---|---|---|---|---|---|---|
| Top-50 combinations holding or growing value share | 26 | 33 | 30 | 32 | 38 | 31 | 28 | 29 | 26 |
The company's characterisations of aggregate share vary slightly by document and the distinction is worth keeping straight. The quarter's global aggregate share was described as in line with the prior year. The fiscal-year slide says aggregate value share was slightly down. The call says trends improved in the back half and the company exited the year flat. All three can be true at once, and together they describe stabilisation at a lower level rather than recovery.
"our global share has now stabilized and has been flat for 3-month periods. I think that is a big step forward. More recently, and 1 month does not tell you much, but the last volume share month inflected, and volume share is sometimes a good predictor of the status on user growth."
— Shailesh Jejurikar, President and CEO
Assessment: A single month of volume-share inflection, hedged by management itself, is not enough to offset a fiscal year in which the breadth metric fell to an eight-year low. This is the number that most directly contradicts the reinvestment case: 410 bps of incremental marketing in the quarter, and the share scoreboard went backwards.
4. The $1 billion headwind that did not shrink when oil did
At the April call, management sized the fiscal 2027 input-cost headwind at roughly $1B after tax on an assumed Brent price near $100. Three months later the assumed Brent price is $90 and the headwind is still $1B. The composition changed rather than the total.
"You likely note that our current estimated cost impact is the same as we projected last quarter, but at a somewhat lower oil price. This is due to a larger impact from the non commodity elements of the supply chain, like ocean freight and trucking surcharges, supplier inflation and force majeure premiums."
— Andre Schulten, CFO
Management further explained that most of the impact lands in the first half of fiscal 2027 because those materials were produced when crude was above $100, and that the $90 assumption blends realised prices since March 2026 with futures through February 2027.
Assessment: This is the single most important disclosure of the quarter and it is a negative revision dressed as a repeat. A 10% lower oil assumption producing an identical cost hit means the non-crude portion of the supply-chain inflation grew by roughly the amount crude relief provided. It also removes the cleanest upside path in our prior thesis: we said we would revisit the rating on oil de-escalation, and oil de-escalated by $10 a barrel without moving the number.
5. Where the margin pressure moved: from cost of goods to marketing
Core gross margin was flat after falling 100 bps in Q3, which looks like progress until the bridge is read. The 160 bps of gross-margin productivity plus 40 bps of net tariff recovery plus 20 bps of miscellaneous items plus 10 bps of pricing exactly cancelled 120 bps of unfavorable mix plus 70 bps of product and package reinvestment plus 40 bps of commodity cost. Below that line, core SG&A rose 130 bps as 410 bps of reinvestment overwhelmed 300 bps of productivity.
Pressed on whether that construct implies gross-margin compression and limited SG&A growth in fiscal 2027, management described the investment framework, the flow-through of restructuring savings, and an intention to make media spend more effective, without addressing the margin direction the question asked about.
"We have delivered record cost of goods productivity in the fiscal we just closed. And we will do that again if not more. And that is our path to get to a reasonable EPS outcome with the cost headwinds we talked about while maintaining investment in the business and providing the value balance that consumers need to give us the share growth that we want."
— Andre Schulten, CFO
Assessment: Consistent with the "we do not target gross margin" posture management set out in April, and consistent as a philosophy. As a forecasting input it leaves investors with 460 bps of gross productivity, no margin target, and an EPS guide of 0% to 3%. Productivity of that magnitude reaching the P&L as flat earnings is the definition of a business whose reinvestment is not yet paying.
6. The first fiscal 2027 guide, and why it lands under the Street
The guidance withheld in April arrived, and it came in below consensus on both lines. Core EPS is guided to $6.89 to $7.11, a midpoint of $7.00 against a Street sitting near $7.04. Organic sales are guided to 1% to 3%, a midpoint of 2% against a Street near 2.7%. All-in EPS growth of 1% to 5% includes $0.13 to $0.17 of non-core restructuring charges.
The construction of the top-line range is unusually explicit and worth restating, because it means the midpoint already assumes share gains.
"if the categories grow at 2, and we have underlying growth of 2.5, that would require share growth. But would leave us at the midpoint of the range from a organic sales growth standpoint."
— Andre Schulten, CFO
Management also volunteered an explicit quarterly steer, which P&G rarely does.
"While we do not typically provide quarterly guidance, we estimate the cost dynamic will cause Q1 EPS to be down 5% or more versus prior year."
— Andre Schulten, CFO
Assessment: The guide is honest and probably achievable, which is different from being good. A midpoint that requires share gains just to hit 2% organic, in a year that opens with core EPS down 5% or more, is a low bar built on an assumption the company missed in fiscal 2026. The conservatism P&G is known for cuts both ways here: it makes the guide credible and it makes the upside case dependent on the same market-share execution that has now disappointed for two consecutive years.
7. Greater China: the one unambiguous turn
China grew 4% organic in the quarter and 4% for the fiscal year, and the share story finally caught up with the sales story.
"We are now growing share in China for the first time in 15 quarters, driven by fundamental changes we made similar to what we are doing in the company. We changed our go-to-market. We changed our brand building systems and processes and capabilities"
— Shailesh Jejurikar, President and CEO
Management was careful to say the growth is not market-assisted. The China market remains down roughly 2% on the most recent reading, so this is share capture in a contracting category set. Baby Care is now the number-one brand position in the market, SK-II grew 8% excluding travel retail, and Fabric Care and Feminine Care are gaining share. The acknowledged gaps are the lower tier of hair care, Oral Care, and mass skin.
"China market continues to be challenged. So it is not a tailwind that we are getting."
— Andre Schulten, CFO
Assessment: This is the strongest evidence in the print that the intervention playbook works when it is given enough time. It is also, at roughly the scale China represents for P&G, not large enough to change the consolidated arithmetic. We treat it as validation of the method and as optionality on the pace of the North American and European repair, not as a driver of the fiscal-2027 number.
8. The core-relaunch playbook, and its limits
The intellectual centre of the call was the "stronger core and bigger more" framing: improve the base proposition on the biggest brands rather than chasing incremental new forms. Tide is the proof point management keeps returning to, and the results exceeded their own expectation.
"It is absolutely the basis on which we will continue to drive more of this across the company. It is what we refer to it as stronger core, that is what we mean. You can take any of our brands, take Head & Shoulders. 85% of our user base is on the base Head & Shoulders."
— Shailesh Jejurikar, President and CEO
Management was explicit that this route generally does not come with price. The Tide upgrade was delivered at an unchanged price point, and the broader framing is a return to a volume-and-price growth model after a post-pandemic period in which price did all the work.
"we have had the post-COVID period 100% of growth driven by price. We will return, and you see that in the construct, to a more balanced model where we see both price and volume being drivers of our top-line growth."
— Andre Schulten, CFO
Assessment: Strategically we think this is the right answer, and it is a better one than blanket pricing into a cost cycle. Financially it is dilutive twice over: better product at the same price compresses gross margin, and the marketing to communicate it compresses SG&A. That combination is exactly what fiscal 2026 delivered, and management is telling investors to expect more of it.
9. Family Care, private label, and the vertical portfolio
Family Care was the only category to decline for the full fiscal year and lost 0.4 points of global value share in the quarter. Management's diagnosis is specific and price-led: the commodity-linked pricing of recent years opened too large a gap to private label in some channels, and that gap is now being closed. The stated remedy is a reactivated vertical portfolio under Charmin and Bounty plus innovation on the base.
"this category only grows if Charmin and Bounty grow"
— Andre Schulten, CFO
Assessment: Naming the problem as a price-point gap is more useful than the "category dynamic" framing used in prior quarters, and the first user growth in the category is a real leading indicator. But the fix is a price-gap correction in P&G's most commodity-exposed category, arriving in the same year that pulp, energy and freight costs are guided to take $1B out of earnings.
10. Capital allocation held, cash conversion guided lower
P&G returned more than $15B in fiscal 2026, comprised of $10.2B of dividends and $5.0B of buybacks, and delivered 100% adjusted free-cash-flow productivity against an 85% to 90% guide. The April dividend increase of 3% was the 70th consecutive annual raise and the 136th consecutive year of paying a dividend. Fiscal 2027 plans call for the same roughly $15B split, more than $10B of dividends and about $5B of repurchases, but with free-cash-flow productivity guided back down to 85% to 90% and capital spending at 4.5% to 5.5% of sales against 5.1% delivered.
The balance sheet supports it comfortably. Net debt finished the year at $24.2B against $25.0B a year earlier, and the dividend consumed 62% of core earnings and 64% of GAAP earnings.
Assessment: The capital-return machine is intact and is the floor under the equity. It is also, at a flat $15B in a year of 0% to 3% earnings growth, no longer a source of incremental support. The buyback shrinks the share count about 1.3% a year, which is now a meaningful fraction of total EPS growth rather than a supplement to it.
11. The Moeller board exit and a November Investor Day
The call opened with the announcement, carried in a separate release the same morning, that Jon Moeller will retire from the board after 38 years with the company, having served as treasurer, chief financial officer, chief operating officer, chief executive and executive chairman. The current chief executive delivered the tribute. Separately, management closed the call by announcing an Investor Day on November 19 in Cincinnati.
"Just one last piece before we sign off. I want to remind you that our Investor Day will be on Thursday, November 19 here in Cincinnati. We will be sending out invitations tomorrow morning."
— Shailesh Jejurikar, President and CEO
Assessment: The board departure completes a leadership transition rather than starting one, and removes the last institutional anchor to the prior strategy. That cuts both ways: full ownership of the current plan now sits with the incumbent team, which is cleaner accountability, and there is no longer a predecessor on the board to slow a portfolio decision. The November Investor Day is the more actionable item. It is the first scheduled forum in which management has to attach medium-term numbers to the "CPG company of the future" language, and it is the most likely catalyst for the multiple in either direction.
Guidance & Outlook
Fiscal 2027 guidance is the reason this print mattered. It was deferred at the April call specifically so management could size the Middle East cost shock, and it arrived below the Street on both the top and bottom line.
| Metric | FY2026 actual | FY2027 guide | Implied | Street going in |
|---|---|---|---|---|
| Organic sales growth | +1% | +1% to +3% | midpoint +2% | ~+2.7% |
| All-in net sales growth | +3% | +1% to +3% | midpoint +2% | n/a |
| Core EPS growth | +1% | 0% to +3% | $6.89 to $7.11, midpoint $7.00 | ~$7.04 |
| Currency-neutral core EPS growth | 0% | 0% to +3% | FX neutral to the guide | n/a |
| All-in (GAAP) diluted EPS growth | +2% | +1% to +5% | off a $6.62 base | n/a |
| Non-core restructuring charges | $0.37 | $0.13 to $0.17 | remainder of the June 2025 plan | n/a |
| Core effective tax rate | 20.8% (GAAP) | ~20% | in line with FY26 | n/a |
| Adjusted FCF productivity | 100% | 85% to 90% | guided down | n/a |
| Capital spending (% of sales) | 5.1% | 4.5% to 5.5% | broadly unchanged | n/a |
| Dividends | $10.2B | >$10B | maintained | n/a |
| Share repurchases | $5.0B | ~$5B | maintained | n/a |
| Q1 FY27 core EPS | $1.99 (Q1 FY26) | "down 5% or more" | implies ~$1.89 or below | n/a |
The fiscal 2027 earnings headwind, itemised
| Item | After-tax impact | Note |
|---|---|---|
| Raw materials, energy, transportation and related premiums | ~$1,000M | Assumes an effective Brent price of $90/bbl; first-half weighted |
| Higher net interest expense | ~$150M | n/a |
| Lower non-operating income | ~$150M | Laps the FY26 Glad joint-venture gain |
| Unfavorable foreign exchange | ~$50M | n/a |
| Total | ~$1,350M ("roughly $1.4 billion") | $0.56 per share, an 8% drag on core EPS growth |
Implied ramp: Guidance of 0% to 3% core EPS growth while absorbing an 8-point drag means management is underwriting roughly 8 to 11 points of underlying earnings growth, funded by productivity, the flow-through of restructuring savings, and about 1.3 points of share-count reduction. That is a demanding internal build. With Q1 core EPS guided down 5% or more, the remaining nine months must deliver roughly 2% to 5% growth to reach the range, and management's own framing is that the cost pressure anniversaries in the second half. The year is therefore back-half weighted in both earnings and, per management, in the scaling of the four capability programmes.
Street at: Consensus entering the print sat near $7.04 of core EPS and roughly 2.7% sales growth for fiscal 2027. The guide midpoint is below both. The near-term reset is already visible in the September-quarter estimate, which has moved to about $1.89, consistent with the guided step down.
Guidance style: Characteristically conservative, and unusually well-specified this time. Management named the category-growth assumption (2%), the underlying company growth needed to reach the midpoint (2.5%), the restructuring drag on organic (30 to 50 bps), the oil assumption ($90), and a quarterly EPS steer. The low end of the top-line range protects for softer market growth; the high end requires both faster categories and share gains. P&G has a long record of guiding low and landing inside, and fiscal 2026 landed inside every range. The concern is not credibility of the guide. It is that the guide describes a year of no earnings growth at the low end and 3% at the high end.
The comparison that matters. Management is guiding fiscal 2027 core EPS to a midpoint of $7.00. Fiscal 2024 core EPS was $6.59 and grew 12%. Fiscal 2025 was $6.83 and grew 4%. Fiscal 2026 was $6.89 and grew 1%. On the guide midpoint, fiscal 2027 grows 1.6%. Three consecutive years of low-single-digit core-EPS growth, with the multiple still near 21x, is the arithmetic of this rating change.
Analyst Q&A Highlights
When the return to category outperformance actually arrives
The opening question set the frame for the whole session: more than a year after the restructuring was announced, share is flat rather than growing, and the questioner wanted a timeline for consistent outperformance. The answer was a tour of regional proof points, China, Latin America, the Gulf, Turkey, Europe, each with a user-growth statistic attached, and an explicit note that the North American interventions started latest and are weighted to the July-to-December semester.
Q: "So, just looking forward to fiscal 2027, what are the biggest areas or initiatives left to put in place versus what is already been implemented organizationally in your restructuring? And just as you think about fiscal 2027, you think you can consistently return to sales outperformance versus your categories at some point? Any thoughts on timing there?"
— Dara Mohsenian, Morgan Stanley
A: "So overall, long winded answer, but I feel good about the progress we are making I feel confident based on the intervention we made and the timelines we have that we are on track. And which is why even though our sell-in, sell-out was mismatched, I good, because as long as the consumption is strong, I am very confident that we will have strong sales."
— Shailesh Jejurikar, President and CEO
Assessment: The regional evidence is genuine and the user-growth metrics (Latin America from under 10% of the business growing users three years ago to over 55%, the Gulf from under 5% to 60%) are the most persuasive operational data on the call. But the question asked for a timing commitment on category outperformance and did not get one. "On track" without a date, in the fourth consecutive quarter of that framing, is the answer that keeps this a show-me story.
The share scoreboard went backwards, and by how much
A precise and unanswered question. The questioner noted the 23-of-50 figure was a sequential step back and asked what portion of that 23 actually grew share as opposed to merely holding it, then asked which large combinations still need intervention. The response covered enterprise-market strength, the China turn, European fabric-care competitiveness, the US customer-level improvement and the baby-care and family-care roadmaps. It did not supply the split.
Q: "So the you have called out the 23 out of 50 country category combinations held or grew share. I think that was a step back sequentially... But I was curious within that number, what percentage actually grew share within that."
— Lauren Lieberman, Barclays
A: "We are building out that matrix of category-country, customer share growth, and we are increasing the number of greens. Will it be linear? No. But do we have confidence that we exit next year with strong, solidified share growth? Yes."
— Andre Schulten, CFO
Assessment: The grew-versus-held split is the single most diagnostic number an investor could have on the reinvestment thesis, and it was asked for directly and not provided. Given the company voluntarily publishes the combined metric, the absence of the decomposition is conspicuous. We read the non-answer as evidence the mix inside the 23 skews toward "held."
Whether gross margin compresses again and SG&A leverage arrives
The most analytically constructed question of the call laid out a specific premise: modest gross-margin compression for the year, implying SG&A grows little or shrinks, implying operating leverage. It asked management to confirm or reject that construct and to characterise the absolute level of brand investment going into fiscal 2027. The answer described the productivity flow-through, the completed headcount and market restructuring, the intent to improve media effectiveness rather than cut spend, and record cost-of-goods productivity. The words "gross margin" did not appear in the response.
Q: "Number 1 is the is my premise, you know, somewhat logical around a bit of gross margin compression and thereby SG and A? Does not grow a whole lot? And if so, can you just give us a sense of, yeah, how you would view the full investment suite over the last several years, say, fiscal 2026 and into 2027"
— Chris Carey, Wells Fargo
A: "We have remained fully invested in the business. And if you look at our media spend and advertising spend over the last 3 to 5 years, the only way we have gone is up. And as I said, I think neither I nor Shailesh believe that 100% of that spending has been effective. And we will work to increase the effectiveness"
— Andre Schulten, CFO
A: "So there is investment in brand building, which shows up as advertising cost. there is investment in product, very often like we did on Tide. To significantly improve value. So we are very choiceful and disciplined of where we are investing for that brand in that country to get the maximum lift."
— Shailesh Jejurikar, President and CEO
Assessment: This is the exchange that most constrains the model. Management has now declined to give a gross-margin direction for two consecutive quarters, consistent with its stated position that margin is an outcome rather than a target. The admission that not all of the increased media spend has been effective is candid and, read against a year in which the share metric fell to an eight-year low, is the most important thing said on the call about the return on reinvestment.
Unpacking the 1% to 3% organic range
A question about the internal construction of the guide produced the most useful disclosure of the session. The response laid out the category-growth assumption, the underlying company growth required, and the restructuring drag, which together reveal that the midpoint already embeds share gains rather than treating them as upside.
Q: "But on the high end, you mentioned, you know, assume acceleration in category growth and market share performance. But I think, historically, you know, category growth alone would already put you towards the higher end of that range. So could you maybe just unpack what is embedded from a category growth standpoint in the outlook?"
— Peter Grom, UBS
A: "So if I dissect the guidance on the top-line range, the base assumption is category growth at the current levels we are seeing in the market, which is 2%. that is a global number. So 2% value growth is the center line. To deliver 2% organic sales growth within that would require us to grow about 2.5 points. Because we have about a 40, 50 basis points headwind from the market restructuring on the top-line"
— Andre Schulten, CFO
Assessment: Straightforward, quantified and helpful, and it reframes the guide unfavourably. The midpoint is not a neutral share assumption; it requires P&G to grow 0.5 points faster than its categories in a year that just ended with the breadth metric at an eight-year low. The low end of the range, not the midpoint, is the no-share-gain scenario.
Whether the shipment-consumption gap is a P&G-specific problem
Because the sell-in and sell-out disconnect has recurred across several quarters, one line of questioning asked whether something about P&G's brands, strategy or retailer concentration makes it more exposed than peers. The answer was a size-and-velocity argument rather than a structural defence, followed by a note that the direction of the gap is not uniform across categories.
Q: "I just want to go back to start with, go back to the gap between the shipments and consumption And I was just wondering, this has been going on for a while now. Right? And I am just wondering if there is anything that is more distinct with Procter's business compared to other of your competitors? Because it does seem to be a little bit more of an issue for you guys."
— Robert Ottenstein, Evercore ISI
A: "I think it is a very simple answer. We are bigger than everybody else. And we have higher velocity than everybody else. So if you need to reduce your inventory, quickly, you focus on the biggest brand on the shelf that has the highest velocity, because that is how you can get your inventory dollars down."
— Andre Schulten, CFO
Assessment: Persuasive as mechanics and unhelpful as a forecast. If scale is the reason retailers de-stock P&G first, the exposure is permanent, not cyclical, and it will recur every time the trade tightens working capital. Management's own remedy, grow fast enough that the noise is invisible, is a restatement of the problem rather than a solution to it.
Whether the low-growth regime is structural, and whether the portfolio should change
The most strategically ambitious question of the call had two halves: is the current 1%-type growth environment lasting rather than transitory, and is there anything about the current category portfolio that should be reconsidered by management and the board. The response addressed the first half at length through demographic shifts, faster-growing segments, expandable-consumption adjacencies and core-proposition activation. The second half went unaddressed.
Q: "if you would indulge me, sort of as part of the strategy, is there anything that gives you pause now about the current portfolio or the sort of relative attractiveness of these categories that should potentially be reconsidered by you and by the Board."
— Kevin Grundy, BNP Paribas
A: "So we feel there is plenty of growth opportunity. We are not constrained by the current consumer environment. We know when we innovate well against the right growth opportunity areas, we can get back to high growth rates."
— Shailesh Jejurikar, President and CEO
Assessment: An explicit invitation to discuss portfolio reshaping, declined without acknowledgement. The word "divest" does not appear anywhere in the call. That is a defensible posture three months before an Investor Day, and it also means the single largest potential value-creation lever at a company with a decelerating growth profile remains entirely undiscussed in public.
What the Tide relaunch implies for the volume-versus-price mix
A question on whether the Tide result exceeded internal expectations, and whether replicating it implies a growth algorithm weighted more to volume than to price, drew the most unguarded answer of the call and a direct statement about the composition of future growth.
Q: "I think you referenced high-single-digit growth. Now is that in line or better than you would have expected? And how much is what I would think assume is the apparent success of that move much will that make you consider such an approach in other areas? So does that then-- would it be then logical to assume within the algorithm that we are going to get more volume than price going forward?"
— Edward Lewis, Rothschild & Co Redburn
A: "I would let me go back to the Tide as the basis and then build from there. So it beat our expectations is a simple answer. When you put such a massive investment in product performance on such a large part of the business. It is very difficult to estimate a number like high-single-digit growth."
— Shailesh Jejurikar, President and CEO
Assessment: The candour is welcome and the strategic read is right: better product at an unchanged price is a more durable route to users than promotion. The financial implication is the part investors should hold onto. A playbook whose signature move is "significantly better product, same price," rolled out across the biggest brands, is a plan to buy volume with gross margin. It should work on the top line and it will not repair the margin line.
Pricing versus promotion in a fresh inflation cycle
With cost inflation arriving alongside deliberate price interventions in baby care and family care, a question asked how the two forces net out and requested the volume, price and mix composition embedded in the fiscal 2027 organic guide. The answer described promotional intensity returning to pre-pandemic levels, reaffirmed that promotion is a trial tool rather than a growth strategy, and committed to continued price-mix contribution. It gave no composition split.
Q: "So maybe can you help us understand within your organic guidance contribution from volume, price, and mix in 2027?"
— Filippo Falorni, Citi
A: "But we do not believe that promotion in any way, shape, or form is a way to build the business, or to acquire users on a sustainable basis. So we will use it where it makes sense, it is not part of our desired business building strategies. We expect to return to pre COVID level. We are cognizant of that, and we have built that into our assumptions. But we will continue to drive pricemix in this in this year, like we have done in 20 out of 21 years."
— Andre Schulten, CFO
Assessment: The "20 out of 21 years" of positive price-mix is a real record and a fair rebuttal to the idea that pricing power has evaporated. But in the quarter just reported, pricing contributed zero and mix contributed zero, and in the segment with the most private-label exposure pricing was negative. The commitment is to the historical pattern; the evidence in hand points the other way, and no forward composition was offered to bridge the two.
What They're NOT Saying
- How much of the 23-of-50 actually grew share: the split between combinations that grew share and those that merely held was requested directly and never provided. P&G publishes the combined figure voluntarily every quarter, so the decomposition exists internally. Its absence, in the year the metric fell to an eight-year low, is the most informative silence on the call.
- Any fiscal 2027 gross-margin or operating-margin direction: the phrase "gross margin" was used on the call only in describing fiscal 2026 results and in the analyst's question. Management has now gone two consecutive quarters without giving a forward margin direction, having stated in April that it does not target the metric. With core operating margin down 130 bps in the quarter and 70 bps for the year, this is a material forecasting gap rather than a philosophical footnote.
- The size of the fiscal 2027 productivity programme: fiscal 2026 delivered $2.8B before tax across cost of goods and SG&A. The only forward statement was that cost-of-goods productivity will be repeated "if not more." Productivity is the entire stated offset to a $1.35B after-tax headwind, and it is unquantified.
- The volume, price and mix composition of the fiscal 2027 organic guide: asked explicitly, answered with a philosophy of pricing with innovation and a reference to a 21-year price-mix record. Given that Q4 delivered zero from each of volume, price and mix, and that the "stronger core" playbook is by construction price-neutral, this composition is the difference between a margin-accretive and a margin-dilutive path to the same 2%.
- Portfolio reshaping: a direct question about whether any current categories should be reconsidered by management and the board was left unanswered. The word "divest" does not appear in the call. For a company with three consecutive years of low-single-digit core-EPS growth and a category mix that includes its worst-performing business at an eight-year share low, the absence of any portfolio discussion is notable heading into a November Investor Day.
- Any quantification of Tide Evo: Evo is described as the biggest innovation in laundry, protected by more than 50 granted patents, with national expansion "on track" and full-scale launch support planned this fiscal year. No distribution figure, no revenue contribution, no share point, no launch-market read. It has now been discussed across multiple calls without a single number attached.
- Quarter-to-date trading: July commentary was requested and not given. The only forward-looking data point offered for the September quarter is the "down 5% or more" EPS steer, which is a cost statement rather than a demand statement.
- Forward tariff recovery: the quarter benefited by 40 bps of core gross margin from recognised tariff recoveries, which is what held core gross margin flat. No figure was given for what remains recoverable, over what period, or whether any of it is embedded in the fiscal 2027 guide.
- Restructuring completion detail: the only update was that "half of the headcount reduction has been executed" and that the major market restructuring is complete, with over half of the $1B to $1.6B of charges incurred in fiscal 2026. There was no updated headcount target, no completion date, and no savings figure attributable to the plan specifically.
- What changes if oil goes the other way: management said it feels comfortable with the guide midpoint if the Middle East situation holds. It did not size the upside if Brent falls below the $90 assumption, which is asymmetric disclosure given that the $100-to-$90 move just produced no benefit at all.
Market Reaction
- Pre-print setup: PG closed at $148.88 on July 28, up 3.9% year to date but down 4.9% over the trailing twelve months and up just 0.3% over the trailing 30 days. The 52-week closing range was $138.04 to $167.20, so the stock entered the print in the lower half of its range and roughly 4.6 points behind the S&P 500's 8.5% year-to-date gain.
- Reaction session (July 29, before the open): shares gapped down to open at $141.38, 5.0% below the prior close, and traded as low as $140.20, down 5.8%, before recovering through the day.
- Close: $146.10, down 1.9% or $2.78, on 14.6M shares against an 8.9M 30-day average, 1.6 times normal volume.
- Relative: the S&P 500 fell 1.5% the same session. PG's underperformance versus the index was roughly 4 points at the open and about 0.4 points by the close.
The shape of the session is more informative than the closing number. The gap down priced the guide: a revenue miss, flat organic, and a first fiscal 2027 outlook below consensus on both lines, with an explicit warning that the September quarter's earnings would fall 5% or more. That is a coherent 5% reaction for a staple whose multiple is built on predictability.
What recovered three quarters of it was the call. Management gave the first-half weighting of the cost headwind, the China share turn, the North American consumption number, the Family Care user growth, and the November Investor Day date, and the market took the view that fiscal 2027 is a trough year with a scheduled catalyst rather than the start of a re-rating. It is also worth noting the index fell 1.5% that day, so part of the closing gap simply reflects a weak tape.
We think the open was closer to right than the close. The market repriced the guide correctly and then discounted it on the strength of qualitative reassurance that has been offered, in similar form, for four consecutive quarters. A defensive name that closes down only 1.9% on a print containing double-digit profit declines in every segment and an eight-year low in the share metric has not fully absorbed the news.
Street Perspective
Debate: Is fiscal 2027 a trough year or the new run rate?
Bull view: The cost headwind is explicitly transitory and first-half weighted, built on materials produced when crude was above $100. Strip the $0.56 per share of cost and below-the-line drag and the underlying earnings algorithm is 8% to 11%. Buying at 21x a suppressed $7.00 is buying roughly 19x a normalised number, with the restructuring savings and the four capability programmes still to flow through.
Bear view: Core EPS growth has now run 12%, 4%, 1% and is guided to 1.6% at the midpoint. Organic has run 2%, then 1%, guided to 2%. Two of those four years had no oil shock. Calling fiscal 2027 a trough requires believing the deceleration is entirely exogenous when the share scoreboard says otherwise.
Our take: The bull arithmetic is real and the bear pattern-recognition is more persuasive. The company has produced three consecutive years of low-single-digit core-EPS growth against a 3% to 5% top-line algorithm it has not reached in either of the last two years. Even granting the full trough thesis, the re-rating requires evidence that will not exist before the second half of fiscal 2027 at the earliest.
Debate: Is the reinvestment buying anything?
Bull view: The evidence is in the regional data rather than the consolidated line. China is growing share for the first time in fifteen quarters. Latin America has moved from under 10% to over 55% of the business growing users. The share of top US customer-brand combinations holding or growing share went from under 10% in the first half to about 50% in the second. Tide original liquid went from decline to high-single-digit growth. Those are consequences of the spend, and they lead reported sales.
Bear view: 410 bps of incremental marketing in the quarter produced 0% organic sales, 23 of 50 on the share metric, and a full year at 26 of 50, the weakest in eight years. Management itself conceded that not all of the increased media spend has been effective. If the leading indicators were as strong as claimed, they would be showing up in the aggregate by now.
Our take: Both are describing real data and the disagreement is about lag length. The regional proof points are genuine and the method plainly works where it has had time, which is the strongest argument for patience. But an investor is being asked to pay a premium multiple for a second consecutive year while that lag runs, and the one metric that would settle it, the growth-versus-hold split inside the 23, was requested and withheld.
Debate: Does a de-rated Dividend King have downside?
Bull view: At roughly 21x with a 3.0% yield covered at a 62% core payout, a 70-year raise streak, $15B of annual capital return, net debt of $24.2B against nearly $20B of annual operating cash flow, and the stock in the lower half of its 52-week range, the downside is structurally cushioned. Staples multiples do not break for a cost cycle.
Bear view: 21x is a premium multiple that has historically been paid for mid-to-high single-digit compounding. At 0% to 3% guided growth, there is nothing for the multiple to discount. A drift to 19x on the guide midpoint is $133, and the dividend does not bridge that.
Our take: The bear case on the multiple is the sharper argument and it is the crux of our downgrade. This is not a solvency or franchise question; the balance sheet and the dividend are unimpeachable. It is a question of what 21x is buying. Three consecutive years of roughly 1% to 2% core-EPS growth, with the fourth guided to the same, is a multiple looking for a justification.
Model Update Needed
| Item | Prior assumption | Suggested change | Reason |
|---|---|---|---|
| FY26 organic growth | ~+2.0% | +1% (actual) | Q4 organic 0%; full year closed at the guide's lower half |
| FY26 core EPS | ~$6.85 (low end) | $6.89 (actual) | Landed modestly above the "low end" steer on tax and the tariff recovery |
| FY27 organic growth | flat to modest (wide band) | +1.5% to +2.0% | Guide midpoint 2% requires share gain; we assume the low half given the FY26 share outcome |
| FY27 core EPS | flat to modestly up (wide band) | $6.90 to $7.00, base case ~$6.95 | Below the $7.00 guide midpoint; the midpoint embeds share gains and no further cost creep |
| Core gross margin | -80 to -100 bps | -30 to -60 bps | Q4 held flat on tariff recovery; FY27 commodity drag offset by record COGS productivity |
| Core operating margin | not separately modeled | -50 to -100 bps | Marketing reinvestment continues at the elevated FY26 rate with no margin target given |
| Adjusted FCF productivity | 85%-90% | 90%-95% | FY26 delivered 100% against the same guide; management guides conservatively here |
| Capital return | ~$15B | ~$15B | Confirmed for FY27: over $10B dividends plus ~$5B buyback; ~1.3% annual share shrink |
| FY28 core EPS | n/a | $7.35 to $7.60 | Assumes the cost headwind anniversaries and organic settles at 2% to 3%; the trough-year recovery case |
Valuation impact: We move fair value to a $132 to $148 range, from $150 to $165. The band is 19.0x to 21.0x the fiscal 2027 core-EPS midpoint of $7.00, with the low end also approximating 19.0x the guide floor of $6.89. The midpoint of that band is roughly $140, about 4% below the $146.10 close. Adding the 3.0% dividend yield gives an expected twelve-month total return in the low single digits, before any further multiple compression. That is a below-market expected return, which is what the rating now says.
Thesis Scorecard Post-Earnings
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1: Operational reacceleration, with the H2 turn proven and a sustainable run rate near 3% | Challenged | Q4 organic 0%; management's own clean structural read is 2%, not 3%. Categories growing fell from 10 of 10 to 6 of 10, regions from 7 of 7 to 5 of 7, North America from +4% to -1%. FY26 organic +1%, below FY25's +2%. Status: ON TRACK → AT RISK. |
| Bull #2: Productivity and restructuring self-fund reinvestment | Confirmed | 460 bps of gross productivity in the quarter, $2.8B before tax for the year, record cost-of-goods productivity, half the headcount reduction executed and market restructuring complete. The mechanism works; what it funds has not yet paid. Status: ON TRACK. |
| Bull #3: Capital-return durability and defensive quality | Confirmed | $15.3B returned in FY26, 70th consecutive dividend increase, 62% core payout, ~3.0% yield, net debt down to $24.2B, and ~$15B planned again for FY27. Status: ON TRACK. |
| Bear #1: Organic growth stall and US share loss | Confirmed / re-escalating | North America organic -1% with a 3-point sell-in gap; 23 of 50 combinations held or grew share in the quarter and 26 for the year, level with FY18 and the weakest since. Global aggregate value share slightly down for the year. Status: CONTAINED → EMERGING. |
| Bear #2: Margin and cost pressure, including the oil shock | Confirmed / materialising | The ~$1B after-tax headwind is now inside guidance at $0.56 per share, an 8% drag, and did not shrink when the Brent assumption fell from ~$100 to $90. Core operating margin -130 bps in the quarter. Q1 FY27 core EPS guided down 5% or more. Status: EMERGING → MATERIALIZING. |
Overall: The thesis weakened on both sides. The bull pillar we upgraded to ON TRACK one quarter ago did not survive contact with the fourth quarter, and the bear point we downgraded to CONTAINED has re-escalated. The two pillars that held, productivity and capital return, are both mechanisms rather than outcomes: they describe how P&G funds its investment and returns its cash, not whether the investment is producing growth. On the evidence of fiscal 2026, it is not.
Action: Downgrading to Underperform from Hold, with fair value of $132 to $148 against a $146.10 close. Our April note named two downgrade triggers, Q4 organic falling materially below 2% and the productivity offsets visibly falling short against the oil headwind. Q4 organic came in at 0% and the headwind held at $1B on a $10-per-barrel-lower crude assumption while the resulting guide landed under consensus. Both fired. We would return to Hold on a move toward the low-$130s, which would price the guide at 19x with the dividend intact, or on evidence in the September and December quarters that organic is running at 2% or better with the share metric improving. We would consider Outperform only on a genuine strategic reset, which most plausibly means portfolio action or a credible medium-term algorithm presented at the November 19 Investor Day.